Q-omics provides the consensus-scored TGFBR3L profile across patient tissues and cancer cell-line models. TGFBR3L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TGFBR3L is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TGFBR3L RNA expression shows 14,469 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where TGFBR3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGFBR3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGFBR3L survival associations across molecular data types. TGFBR3L RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGFBR3L RNA expression–survival associations across cancer types. High TGFBR3L expression shows unfavorable associations in ACC, BLCA, COAD, CHOL and READ, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TGFBR3L RNA expression.
This table summarizes TGFBR3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TGFBR3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGFBR3L shows lower tumor expression in KIRC and COAD and higher tumor expression in THCA, LUAD, HNSC and LUSC. The THCA box plot shows higher TGFBR3L RNA expression in tumor versus normal tissue (log2 FC = +1.502, t-test p < 0.001).
This table shows molecular features associated with TGFBR3L in patient tissues and cancer cell lines. In patient samples, TGFBR3L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TGFBR3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
